Global Markets for Generic Drugs

The global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.

Report Includes

• 38 tables
• An updated review of the global market for generic drugs
• Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025
• Highlights of current and future market potential of generic drugs along with an emphasis on the major generics issue, regulatory landscape and patent cliff within the generic drugs industry
• COVID-19 impact (both short term vs. long term) on the global generic drugs market compared to the overall pharmaceutical industry
• Estimation of the market size and market forecast for pharmaceuticals and generic drugs by the most important geographies and major therapeutic categories of products
• Key M&A deals, collaborations and partnerships, licensing and manufacturing agreements, and other investment strategies within this market
• Competitive landscape of the key players in the global generic drugs market, analysis of company sales data, and structure of the generics industry
• Insight into the pipeline analysis of new and generic drugs and their impact on the growth of the market
• Company profiles of the leading players operating in global generic drugs market including Aspen, Cipla, Lupin, Pfizer, Sanofi, Sun Pharmaceuticals and Teva Pharmaceuticals

The global market for generic drugs should reach $533 billion by 2021 from $352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021.

Report Includes

• An overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
• Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition
• Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity
• Profiles of major players and leading generics companies
• A look at recent merger and acquisition activity

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

Report Includes

• An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
• Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
• Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.

The global generics market is estimated at about $225 billion in 2011. By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion, representing more than 18% of all pharmaceuticals, a projected compound annual growth rate (CAGR) of 9.7% between 2011 and 2016.

• The global market for generic drugs was worth $81 billion in 2008, a figure that is expected to reach $84 billion in 2009. In 2014, the market is expected to amount to $168.7 billion, for a compound annual growth rate (CAGR) of 15% in the 5-year period.
• Sales of U.S. generic drugs currently dominate the market, estimated at $33 billion in 2009 and projected to increase at a CAGR of 10.4% to $54 billion in 2014.
• Japan’s generic drugs market is expected to have the highest rate of growth among major markets at 12.2%, increasing from $5.4 billion in 2009 to $9.6 billion in 2014.

• The U.S. prescription generic drug market is projected to grow from an estimated $11.1 billion in 2001 to more than $19 billion in 2006, representing an average annual growth rate (AAGR) of 11.4%.
• Major growth in the market is projected to derive from the respiratory, central nervous system, gastrointestinal and anticancer therapeutic categories.
• Cardiovascular drugs alone represent nearly 21% of the generic prescription drug market.
• Anti-infectives (14.4%) and antiarthritics/analgesics (14.0%) are the next largest generic drug categories.